NASDAQ:BCELAtreca Stock Price, Forecast & News

Atreca's stock was trading at $17.62 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, BCEL shares have increased by 28.9% and is now trading at $22.71. View which stocks have been most impacted by Coronavirus.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Atreca in the last year. There are currently 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Atreca.

Atreca is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for Atreca.

Atreca (NASDAQ:BCEL) announced its quarterly earnings results on Thursday, May, 14th. The company reported ($0.73) earnings per share (EPS) for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.73). View Atreca's earnings history.

9 brokerages have issued 12-month price objectives for Atreca's shares. Their forecasts range from $16.63 to $33.00. On average, they anticipate Atreca's stock price to reach $27.80 in the next year. This suggests a possible upside of 22.4% from the stock's current price. View analysts' price targets for Atreca.

Media headlines about BCEL stock have trended negative on Sunday, InfoTrie Sentiment reports. The research group ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Atreca earned a media sentiment score of -2.2 on InfoTrie's scale. They also gave news stories about the company a news buzz of 5.0 out of 10, meaning that recent media coverage is somewhat likely to have an impact on the company's share price in the near future. View the latest news about Atreca.

Some companies that are related to Atreca include Apellis Pharmaceuticals (APLS), Opko Health (OPK), Turning Point Therapeutics (TPTX), SAGE Therapeutics (SAGE), IGM Biosciences (IGMS), TG Therapeutics (TGTX), Pacira Biosciences (PCRX), Uniqure (QURE), Corcept Therapeutics (CORT), Eidos Therapeutics (EIDX), Dicerna Pharmaceuticals (DRNA), Xencor (XNCR), Principia Biopharma (PRNB), Prestige Consumer Healthcare (PBH) and Myovant Sciences (MYOV). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Atreca investors own include Editas Medicine (EDIT), Alector (ALEC), Gossamer Bio (GOSS), AbbVie (ABBV), Akoustis Technologies (AKTS), Homology Medicines (FIXX), II-VI (IIVI), Kaleido Biosciences (KLDO), Stoke Therapeutics (STOK) and Akero Therapeutics (AKRO).

(BCEL) raised $126 million in an initial public offering (IPO) on Thursday, June 20th 2019. The company issued 7,400,000 shares at $16.00-$18.00 per share. Cowen, Evercore ISI and Stifel served as the underwriters for the IPO and Canaccord Genuity and Brookline Capital Markets were co-managers.

Atreca trades on the NASDAQ under the ticker symbol "BCEL."

Shares of BCEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of BCEL stock can currently be purchased for approximately $22.71.

Atreca has a market capitalization of $639.06 million. The company earns $-67,480,000.00 in net income (profit) each year or ($4.26) on an earnings per share basis. Atreca employs 85 workers across the globe.

The official website for Atreca is www.atreca.com.

Atreca's mailing address is 500 SAGINAW DRIVE FIRST FLOOR, REDWOOD CITY CA, 94063. The company can be reached via phone at 650-595-2595 or via email at [email protected]